# UMCC 9901: Phase II Study of Tailored-Dose Docetaxel + Trastuzumab in Her-2 Positive Metastatic Breast Cancer

> **NCT00146042** · PHASE2 · COMPLETED · sponsor: **University of Michigan Rogel Cancer Center** · enrollment: 22 (actual)

## Conditions studied

- HER-2 Positive Metastatic Breast Cancer

## Interventions

- **DRUG:** Docetaxel
- **DRUG:** Trastuzumab
- **PROCEDURE:** Erythromycin Breath Test (ERMBT)

## Key facts

- **NCT ID:** NCT00146042
- **Lead sponsor:** University of Michigan Rogel Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1999-03
- **Primary completion:** 2004-03
- **Final completion:** 2005-03
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2012-10-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00146042

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00146042, "UMCC 9901: Phase II Study of Tailored-Dose Docetaxel + Trastuzumab in Her-2 Positive Metastatic Breast Cancer". Retrieved via AI Analytics 2026-09-07 from https://api.ai-analytics.org/clinical/NCT00146042. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*